Zevra Therapeutics, Inc. (ZVRA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Zevra Therapeutics reported revenue of $106.5M, up 350.9% from $23.6M the year before. Net income was $83.2M (a 78.2% net margin), or $1.35 per diluted share. Gross margin was 15.1% and operating margin was -59.1%. Operating activities generated -$1.6M of cash, leaving -$2.4M of free cash flow. At fiscal year end, Zevra Therapeutics held $284.7M in total assets against $130.1M in total liabilities, including $62.4M of cash and equivalents.
Open the full interactive Zevra Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Zevra Therapeutics Key Stats
| Share Price | $10.39 |
|---|---|
| Market Cap | $637.3M |
| P/E Ratio | 7.7 |
| Revenue YoY Growth | +350.9% |
| 52-Week Range | $8.10 – $14.75 |
| Shares Outstanding | 59.2 million (basic, 2026 Q2) |
Zevra Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13.3M | $28.6M | $10.5M | $27.5M | $23.6M | $106.5M |
| Cost of Goods Sold | $18.9M | $20.9M | $53.0M | $77.1M | $97.0M | $90.4M |
| Gross Profit | -$5.6M | $7.7M | $10.1M | $24.5M | -$73.4M | $16.1M |
| Operating Income | -$5.6M | $7.7M | -$42.5M | -$49.6M | -$87.0M | -$62.9M |
| Pre-Tax Income | -$12.8M | -$8.5M | -$42.3M | -$46.0M | -$90.1M | $86.7M |
| Income Tax | -$34,000 | $34,000 | -$786,000 | $0 | $15.4M | $3.4M |
| Net Income | -$12.8M | -$8.6M | -$41.5M | -$46.0M | -$105.5M | $83.2M |
| Diluted EPS | -$3.21 | -$2.11 | — | — | — | $1.35 |
Zevra Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $26.1M | $34.1M | $36.2M | $39.7M |
| Net Income | -$544,000 | $12.2M | $37.9M | $8.8M |
| Diluted EPS | -$0.01 | $0.21 | $0.60 | $0.14 |
Zevra Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $112.3M | $65.5M | $43.0M | $33.8M | $62.4M |
| Current Assets | $8.4M | $115.1M | $93.0M | $86.9M | $86.0M | $223.0M |
| Total Assets | $11.2M | $132.9M | $115.5M | $172.3M | $178.1M | $284.7M |
| Current Liabilities | $7.5M | $4.2M | $11.7M | $73.7M | $34.1M | $39.3M |
| Total Long-Term Debt | $67.7M | — | $12.8M | $5.1M | $59.5M | $61.9M |
| Total Liabilities | $77.6M | $5.8M | $29.7M | $110.5M | $138.5M | $130.1M |
| Shareholders' Equity | -$66.4M | $127.1M | $85.8M | $61.9M | $39.7M | $154.7M |
Zevra Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.9M | $10.4M | -$18.7M | -$33.5M | -$69.7M | -$1.6M |
| Cash From Investing | -$33,000 | -$15.5M | -$36.7M | -$17.4M | -$22.2M | $18.1M |
| Cash From Financing | $2.7M | $113.1M | $8.4M | $28.5M | $82.1M | $12.1M |
| Free Cash Flow | -$2.0M | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.4M |
Figures from Zevra Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Zevra Therapeutics financials page for every line item.
Zevra Therapeutics Company Profile
| Ticker | ZVRA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001434647 |
Frequently Asked Questions
What was Zevra Therapeutics' revenue in fiscal 2025?
Zevra Therapeutics (ZVRA) reported revenue of $106.5M for fiscal 2025.
What is Zevra Therapeutics' annual revenue history?
Zevra Therapeutics' annual revenue by fiscal year: 2020: $13.3M; 2021: $28.6M; 2022: $10.5M; 2023: $27.5M; 2024: $23.6M; 2025: $106.5M.
What was Zevra Therapeutics' net income in fiscal 2025?
Zevra Therapeutics reported net income of $83.2M for fiscal 2025.
What was Zevra Therapeutics' earnings per share (EPS) in fiscal 2025?
Zevra Therapeutics' diluted EPS was $1.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Zevra Therapeutics generate in fiscal 2025?
Zevra Therapeutics generated -$2.4M of free cash flow in fiscal 2025.
What was Zevra Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Zevra Therapeutics reported revenue of $39.7M.
How much debt does Zevra Therapeutics have?
Zevra Therapeutics reported $61.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Zevra Therapeutics are outstanding?
Zevra Therapeutics reported a weighted average of 59.2 million basic shares outstanding in 2026 Q2.
What is Zevra Therapeutics' market cap?
Based on its latest closing price, Zevra Therapeutics (ZVRA) has a market capitalization of about $637.3M.
When does Zevra Therapeutics' fiscal year end?
Zevra Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Zevra Therapeutics headquartered?
Zevra Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.